357 related articles for article (PubMed ID: 15176165)
1. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
2. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
3. Folliculotropic mycosis fungoides responding to bexarotene gel.
Walling HW; Swick BL; Gerami P; Scupham RK
J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
Krönke A; Schlaak M; Arin M; Mauch C; Kurschat P
Eur J Dermatol; 2012; 22(2):259-60. PubMed ID: 22240623
[No Abstract] [Full Text] [Related]
5. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
6. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
7. Follicular mycosis fungoides: variability of a rare entity.
Roeschm A; Schleyer V; Landthaler M; Vogt T
Skinmed; 2005; 4(1):12-7. PubMed ID: 15654159
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
9. [Mycosis fungoid treated with oral bexarotene: study of 13 cases].
Roche Gamón E; Pérez Ferriols A; Vilata Corell JJ; Alegre de Miquel V
Med Clin (Barc); 2007 Nov; 129(17):677. PubMed ID: 18005638
[No Abstract] [Full Text] [Related]
10. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
11. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
Mehlmauer MA
Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
15. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
[No Abstract] [Full Text] [Related]
16. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
Coors EA; Von den Driesch P
Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
[No Abstract] [Full Text] [Related]
17. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
18. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
19. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
20. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J; Cowper S; Moss J; Girardi M
J Drugs Dermatol; 2013 Apr; 12(4):487-9. PubMed ID: 23652902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]